在日本患有棕盆腔 pustulosis 的患者中使用apremilast:一个随机的,第3期试验
Tadashi Terui1, Yukari Okubo2, Satomi Kobayashi3
1Nihon University School of Medicine, Tokyo, Japan.
Journal of the European Academy of Dermatology and Venereology : JEADV
|November 26, 2025
概括
在日本成年人中,阿普雷米拉斯在治疗中度至重度的棕植物 pustulosis (PPP) 中表现出显著的疗效. 这一第三期试验证实了premilast的存在.
科学领域:
- 皮肤病学 皮肤病学
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 棕植物 pustulosis (PPP) 是一种慢性皮肤疾病,有效的治疗选择有限.
- 目前用于PPP的治疗方法往往不能为患者提供足够的缓解.
- 对于中度至重度的PPP,需要新的治疗策略.
研究的目的:
- 评估阿普雷米拉斯特在日本中度至重度棕植物 pustulosis (PPP) 患者的疗效和安全性.
- 根据棕植物性肺瘤区域和严重性指数 (PPPASI) 评分来评估治疗反应.
- 确定阿普雷米拉斯特在PPP患者的长期有效性和安全性.
主要方法:
- 一项为期16周的随机,安慰剂控制,双盲研究,涉及中度至重度PPP的日本成年人.
- 患者接受了阿普雷米拉斯特或安慰剂,随后是开放的阿普雷米拉斯特治疗阶段,长达52周.
- 主要终点是在第16周达到PPPASI总得分 (PPPASI-50) 至少50%的降低.
主要成果:
- 与安慰剂相比,阿普雷米拉斯特治疗导致患者在第16周达到PPPASI-50的比例显著增加 (68%vs35%).
- 在接受连续apremilast的患者中,PPPASI得分的改善持续到第52周.
- 常见的不良事件包括腹,松散的便,头痛和恶心,与阿普雷米拉斯特已知的安全性概况一致.
结论:
- 在日本人群中,阿普雷米拉斯特是适度至严重的棕植物 pustulosis 的有效治疗方法.
- 在这项试验中观察到的安全概况与apremilast的确立安全数据一致.
- 阿普雷米拉斯特为患有这种使人虚弱的皮肤疾病的患者提供了一个有前途的治疗选择.
更多相关视频
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
443
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
443
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
538
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
538
Asthma-III: Symptoms and Complications
3.2K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
3.2K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K


